Cyclophosphamide
Treatment for Chronic Kidney Disease Due To Glomerulonephritis
Typical Dosage: 0.5-1 g/m² IV monthly pulses OR 1-2 mg/kg/day orally
Effectiveness
80%
Safety Score
25%
Clinical Trials
150
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
0.5-1 g/m² IV monthly pulses OR 1-2 mg/kg/day orally
Time to Effect
2-6 weeks
Treatment Duration
3-6 months (induction)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$2,000
Side Effect Mgmt:$3,000
Total Annual:$6,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
2.2
Outcome-Based Costs
Cost per Responder
$8,125
Cost per Remission
$10,833
Comparison vs No treatment
Cost Difference
+$6,500/year
More expensive
QALY Difference
+2.20 QALYs
Better outcomes
Dominance
No dominance
Cyclophosphamide Outcomes
for Chronic Kidney Disease Due To Glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+60%
Common Side Effects
Bone marrow suppression
+65%
Infections
+30%
Hemorrhagic cystitis
+10%
Infertility
+20%
Nausea/vomiting
+45%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov